Navigation Links
Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:10/20/2008

ressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotec
'/>"/>
SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
2. Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
3. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
6. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
7. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
8. BioXcel Forms a Corporate Advisory Board for Its Next Phase of Growth
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PA (PRWEB) January 15, 2014 The Pittcon ... publisher of Food Safety Tech , an e-Journal and ... signed an agreement for the second year for the co-location ... Pittcon 2014. The partnership provides that the registration fee to ...
(Date:1/15/2014)... MINNEAPOLIS , Jan. 15, 2014 ­ RedBrick ... and behavior change technology, today announces that EmblemHealth ... insurer and wellness company, is now providing the RedBrick ... digital coaching program, to all of its members. EmblemHealth ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how ... latent viruses is the Epstein Barr Virus (EBV), and one ... is a chronic inflammatory disease that destroys the body’s joints. ... patients have high concentrations of EBV DNA in their bodies ...
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... NEW YORK, Jan. 20, 2011 Reportlinker.com announces ... in its catalogue: Hospital General ... This is the most comprehensive ... General Radiology and radiology IT systems (PACS) in ...
... using new image and cell technologies have for the ... invading red blood cells. The researchers, from the Walter ... University of Technology, Sydney (UTS), achieved this long-held aim ... microscopy, a technology platform new to Australia. The ...
... German . Development of efficient battery systems for ... Ulm Helmholtz Institute for Electrochemical Energy Storage (HIU). Today, this ... Helmholtz Institute for Electrochemical Energy Storage in Ulm shall be ... high importance to Germany as a location of technology and ...
Cached Biology Technology:Reportlinker Adds Hospital General Radiology Census 2Malaria parasite caught red-handed invading blood cells 2Malaria parasite caught red-handed invading blood cells 3Start of the Ulm Helmholtz Institute 2Start of the Ulm Helmholtz Institute 3
(Date:7/9/2014)... Bacteria found in the bladders of healthy women ... form of incontinence, according to researchers from Loyola ... These findings, published July 9, 2014, in the ... , suggest that bacterial communities may play a ... incontinence (UUI) is a common, yet poorly understood, ...
(Date:7/9/2014)... shifts the geographic ranges in which animals can be ... their parasites. Does an increased range for a host ... Not necessarily, says a team of UC Santa Barbara ... a study published in the Journal of Biogeography ... species, the opposite may happen: Hosts may actually lose ...
(Date:7/9/2014)... nature,s ability to split the water molecule during ... artificial photosynthesis for clean, green and renewable energy ... scientists led by researchers with the Lawrence Berkeley ... Accelerator Laboratory. , Working at SLAC,s Linac ... x-ray laser, the researchers were able to take ...
Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3
... A study supported by the U.S. Department of Health ... findings that suggested the presence of one of several viruses ... The new study also could not find the viruses in ... not have the viruses., The HHS-supported study examined the validity ...
... 22, 2011) -- Maintaining fluid balance in the body ... the mightiest of mammals. By researching recent genomic data, ... intricate process to a turning point in evolution. ... Emeritus, University of Lausanne, along with colleagues Romain A. ...
... E.coli that plays a critical role in defending the ... have the shape of a seahorse by researchers with the ... This discovery holds far more implications for your own health ... protect you from infections by bacteria, viruses, toxins and other ...
Cached Biology News:XMRV, related viruses not confirmed in blood of healthy donors or chronic fatigue syndrome patients 2XMRV, related viruses not confirmed in blood of healthy donors or chronic fatigue syndrome patients 3XMRV, related viruses not confirmed in blood of healthy donors or chronic fatigue syndrome patients 4Fluid equilibrium in prehistoric organisms sheds light on a turning point in evolution 2Close up look at a microbial vaccination program 2Close up look at a microbial vaccination program 3Close up look at a microbial vaccination program 4
... Simplify the process and you reduce ... built into the CEQ 8000. Developed using ... and leadership in capillary electrophoresis technology, the ... analysis system. This system automatically fills the ...
The external laser upgrade for the Molecular Imager FX adds a 635 nm external laser; the 555 nm long pass filter is replaced with a 605 nm band pass filter to distinguish Cy5 from 532 nm excitable dy...
... The APO-BRDU Kit is a 2-color ... total cellular DNA to detect apoptotic cells ... instructions and reagents required for measuring apoptosis ... cells for assessing reagent performance; washing, reaction ...
... The BioGenex VISION Sytem is a ... comes with proprietary digital imaging and ... digital image acquisition, analysis, archving/retrieval and ... a state-of-the-art digital imaging system that ...
Biology Products: